drugset / Trial / NCT00600535
A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the pharmacokinetics (how the drug concentrations change over time) of capsule and tablet formulations of CB7630 (abiraterone acetate) taken with and without food in patients with prostate cancer.
Timeline
- Start
- 2007-07
- Primary completion
- 2012-03
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 1000 mg | Oral |
| Background | Dexamethasone | Small molecule | 0.5 mg | Oral |
| Background | Prednisolone | Other / unclassified | 5 mg | Oral |
| Background | Prednisone | Other / unclassified | 5 mg | Oral |